Hydroxyurea in HIV therapy.
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006678:HIV / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009154:Mutation; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D019562:Viral Load; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D010919:Placebos; D018894:Reverse Transcriptase Inhibitors; D016049:Didanosine; D006918:Hydroxyurea